Nanobiotechnology for the capture and manipulation of circulating tumor cells

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 4, Issue 3, 2012, Pages 291-309

  Hughes, Andrew D ^a   King, Michael R ^a  

^a School of Operations Research and Industrial Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELLS; CANCER THERAPY; CIRCULATING TUMOR CELLS; DETECTION SYSTEM; DIAGNOSTIC TOOLS; DIRECT MANIPULATION; IN-SITU; MALIGNANT CELLS;

BLOOD; CELLS; PATHOLOGY;

MOLECULAR BIOLOGY;

CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; CD34 ANTIGEN; CD45 ANTIGEN; CYTOKERATIN 19; CYTOKERATIN 20; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; MAMMAGLOBIN; MELANIN; MUCIN 1; NANOPARTICLE; PADGEM PROTEIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SILICON DIOXIDE; TELOMERASE REVERSE TRANSCRIPTASE; TITANIUM DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

BIOCOMPATIBILITY; CANCER THERAPY; CELL ADHESION; CELL COUNT; CELL VIABILITY; CIRCULATING TUMOR CELL; DISEASE SEVERITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IN VIVO STUDY; NANOBIOTECHNOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; ANIMAL; BIOTECHNOLOGY; CELL SEPARATION; CYTOCHEMISTRY; METHODOLOGY; NANOTECHNOLOGY; TUMOR EMBOLISM;

ANIMALS; BIOTECHNOLOGY; CELL SEPARATION; HISTOCYTOCHEMISTRY; HUMANS; NANOTECHNOLOGY; NEOPLASTIC CELLS, CIRCULATING;

EID: 84863792455     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.168     Document Type: Review

References (99)

1. Wittekind C, Neid M. Cancer invasion and metastasis. Oncology 2005, 69(suppl 1):14-16.
2. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000, 97:14608-14613.
3. Butler TP, Gullino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975, 35:512-516.
4. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007, 253:180-204.
5. Gassmann P, Enns A, Haier J. Role of tumor cell adhesion and migration in organ-specific metastasis formation. Onkologie 2004, 27:577-582.
6. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572.
7. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000, 6:100-102.
8. Cameron MD, Schmidt EE, Kerkvliet N, Nadkarni KV, Morris VL, Groom AC, Chambers AF, MacDonald IC. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res 2000, 60:2541-2546.
9. Naumov GN, MacDonald IC, Weinmeister PM, Kerkvliet N, Nadkarni KV, Wilson SM, Morris VL, Groom AC, Chambers AF. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002, 62:2162-2168.
10. Nguyen DX, Bos PD, Massague J.Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
11. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. Interactions between cancer cells and the endothelium in metastasis. J Pathol 2000, 190:310-329.
12. Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 2008, 25:335-344.
13. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
14. Panchapakesan B, Caprara R, Velasco V, Loomis J, King B, Xu P, Burkhead T, Sethu P, Stallons L, McGregor W, et al. Micro- and nanotechnology approaches for capturing circulating tumor cells. Cancer Nanotechnol 2010, 1:3-11.
15. De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 2010, 51:1213-1218.
16. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 2010, 20:96-99.
17. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904.
18. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005, 65:713-718.
19. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:7053-7058.
20. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
21. Miller MC, Doyle GV, Terstappen LW. Significance of circulating tumor cells detected by the CellSearch System in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010, 2010:617421.
22. Tong PC, Lee KF, So WY, Ng MH, Chan WB, Lo MK, Chan NN, Chan JC. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004, 27:216-222.
23. Bernards R, Weinberg RA. A progression puzzle. Nature 2002, 418:823.
24. Gray JW. Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 2003, 4:4-6.
25. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
26. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995, 55:1856-1862.
27. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
28. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004, 35:122-128.
29. Zeisberg M, Neilson EG. Biomarkers for epithelialmesenchymal transitions. J Clin Invest 2009, 119: 1429-1437.
30. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005, 11:8006-8014.
31. Goeminne JC, Guillaume T. Detection of circulating tumor by reverse transcriptase polymerase chain reaction. J Clin Oncol 2000, 18:3196-3197.
32. Zieglschmid V, Hollmann C, Bocher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 2005, 42:155-196.
33. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008, 8:329-340.
34. th ed. London: Academic Press; 2009.
35. Goeminne JC, Guillaume T, Symann M. Pitfalls in the detection of disseminated non-hematological tumor cells. Ann Oncol 2000, 11:785-792.
36. Novaes M, Bendit I, Garicochea B, del Giglio A. Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol 1997, 50:209-211.
37. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DS. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 1998, 16:2632-2640.
38. Wu CH, Lin SR, Yu FJ, Wu DC, Pan YS, Hsieh JS, Huang SY, Wang JY. Development of a highthroughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. Int J Cancer 2006, 119:373-379.
39. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009, 115:581-590.
40. Zieglschmid V, Hollmann C, Gutierrez B, Albert W, Strothoff D, Gross E, Bocher O. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res 2005, 25:1803-1810.
41. Zieglschmid V, Hollmann C, Mannel J, Albert W, Jaeschke-Melli S, Eckstein B, Hillemann T, Greten TF, Gross E, Bocher O. Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Res 2007, 27:1823-1832.
42. Zieglschmid V, Hollmann C, Gutierrez B, Krehan A, Kaul S, Bocher O. Heterogeneous expression of tumorassociated genes in disseminated breast cancer cells. Anticancer Res 2007, 27:1769-1776.
43. Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol 2009, 132:237-245.
44. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A, Maes H, Huget P, van Dam P, Vermeulen PB, et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010, 102:276-284.
45. Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, Tazawa H, Kyo S, Mizuguchi H, Urata Y, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest 2009, 119:3172-3181.
46. Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P, Metivier D, Susin SA, Kroemer G, Formstecher P. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999, 59:6257-6266.
47. Hiyama E, Saeki T, Hiyama K, Takashima S, Shay JW, Matsuura Y, Yokoyama T. Telomerase activity as a marker of breast carcinoma in fine-needle aspirated samples. Cancer 2000, 90:235-238.
48. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997, 33:787-791.
49. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010, 31:9-18.
50. Panchapakesan B, Cesarone G, Liu S, Teker K, Wickstrom E. Single-wall carbon nanotubes with adsorbed antibodies detect live breast cancer cells. NanoBioTechnology 2005, 1:353-360.
51. Shao N, Wickstrom E, Panchapakesan B. Nanotubeantibody biosensor arrays for the detection of circulating breast cancer cells. Nanotechnology 2008, 19:465101.
52. Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, Fabbro M, Pantel K. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007, 53:537-539.
53. Alix-Panabieres C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, Choquet-Kastylevsky G, Vendrell JP. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005, 299:177-188.
54. Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, Hoffken K. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005, 43:617-627.
55. Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu CP, Friberg G, Herbst R, et al. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry A 2010, 77:849-860.
56. Harnett MM. Laser scanning cytometry: understanding the immune system in situ. Nat Rev Immunol 2007, 7:897-904.
57. Pachmann K, Heiss P, Demel U, Tilz G. Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC). Clin Chem Lab Med 2001, 39:811-817.
58. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jorke C, Hammer U, Altendorf-Hofmann A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008, 26:1208-1215.
59. Bauer KD, de la Torre-Bueno J, Diel IJ, Hawes D, Decker WJ, Priddy C, Bossy B, Ludmann S, Yamamoto K, Masih AS, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 2000, 6:3552-3559.
60. Krivacic RT, Ladanyi A, Curry DN, Hsieh HB, Kuhn P, Bergsrud DE, Kepros JF, Barbera T, Ho MY, Chen LB, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004, 101:10501-10504.
61. Hsieh HB, Marrinucci D, Bethel K, Curry DN, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, Lazarus N, et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006, 21:1893-1899.
62. Marrinucci D, Bethel K, Bruce RH, Curry DN, Hsieh B, Humphrey M, Krivacic RT, Kroener J, Kroener L, Ladanyi A, et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007, 38:514-519.
63. Huang YF, Chang HT, Tan W. Cancer cell targeting using multiple aptamers conjugated on nanorods. Anal Chem 2008, 80:567-572.
64. Fang X, Tan W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 2010, 43:48-57.
65. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
66. Kim YJ, Borsig L, Han HL, Varki NM, Varki A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol 1999, 155:461-472.
67. Orr FW, Wang HH. Tumor cell interactions with the microvasculature: a rate-limiting step inmetastasis. Surg Oncol Clin N Am 2001, 10:357-381, ix-x.
68. McDonald B, Spicer J, Giannais B, Fallavollita L, Brodt P, Ferri LE. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer 2009, 125:1298-1305.
69. Kohler S, Ullrich S, Richter U, Schumacher U. E-/Pselectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer 2010, 102:602-609.
70. van Ginhoven TM, van den Berg JW, Dik WA, Ijzermans JNM, de Bruin RWF. Preoperative dietary restriction reduces hepatic tumor load by reduced Eselectin-mediated adhesion in mice. J Surg Oncol 2010, 102:348-353.
71. Wojciechowski JC, Narasipura SD, Charles N, Mickelsen D, Rana K, Blair ML, King MR. Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device. Br J Haematol 2008, 140:673-681.
72. Charles N, Liesveld JL, King MR. Investigating the feasibility of stem cell enrichment mediated by immobilized selectins. Biotechnol Prog 2007, 23:1463-1472.
73. Narasipura SD, Wojciechowski JC, Charles N, Liesveld JL, King MR. P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow. Clin Chem 2008, 54:77-85.
74. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005, 5:311-321.
75. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
76. King MR, Western LT, Rana K, Liesveld JL. Biomolecular surfaces for the capture and reprogramming of circulating tumor cells. J Bionic Eng 2009, 6:311-317.
77. Han W, Allio BA, Foster DG, King MR. Nanoparticle coatings for enhanced capture of flowing cells in microtubes. ACS Nano 2010, 4:174-180.
78. Vergaro V, Abdullayev E, Lvov YM, Zeitoun A, Cingolani R, Rinaldi R, Leporatti S. Cytocompatibility and uptake of halloysite clay nanotubes. Biomacromolecules 2010, 11:820-826.
79. Hughes AD, King MR. Use of naturally occurring halloysite nanotubes for enhanced capture of flowing cells. Langmuir 2010, 26:12155-12164.
80. Brenner H. The slow motion of a sphere through a viscous fluid towards a plane surface. Chem Eng Sci 1961, 16:242-251.
81. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
82. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010, 107:18392-18397.
83. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostatespecific antibody. Lab Chip 2010, 10:27-29.
84. Adams AA, Okagbare PI, Feng J, Hupert ML, Patterson D, Gottert J, McCarley RL, Nikitopoulos D, Murphy MC, Soper SA. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J 111'Am Chem Soc 2008, 130:8633-8641.
85. Dharmasiri U, Balamurugan S, Adams AA, Okagbare PI, Obubuafo A, Soper SA. Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis 2009, 30:3289-3300.
86. Wang S, Wang H, Jiao J, Chen KJ, Owens GE, Kamei K, Sun J, Sherman DJ, Behrenbruch CP, WuH, et al. Threedimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angew Chem Int Ed Engl 2009, 48:8970-8973.
87. Rana K, Liesveld JL, King MR. Delivery of apoptotic signal to rolling cancer cells: a novel biomimetic technique using immobilized TRAIL and E-selectin. Biotechnol Bioeng 2009, 102:1692-1702.
88. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002, 16:67-73.
89. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosisinducing ligand. Nat Med 2000, 6:564-567.
90. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000, 60:553-559.
91. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, Zipp F. Human brain-cell death induced by tumour-necrosis-factor-related apoptosisinducing ligand (TRAIL). Lancet 2000, 356:827-828.
92. Huang Z, King MR. An immobilized nanoparticlebased platform for efficient gene knockdown of targeted cells in the circulation. Gene Ther 2009, 16:1271-1282.
93. Galanzha EI, Shashkov EV, Spring PM, Suen JY, Zharov VP. In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res 2009, 69:7926-7934.
94. Kim JW, Galanzha EI, Shashkov EV, Moon HM, Zharov VP. Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nat Nanotechnol 2009, 4:688-694.
95. Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol 2009, 4:855-860.
96. Dobrovolskaia MA, Aggarwal P, Hall JB, McLeland CB, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
97. Karp JM, Hong S, Lee D, Zhang H, Zhang JQ, Resvick JN, Khademhosseini A, King MR, Langer R. Covalent immobilization of P-selectin enhances cell rolling. Langmuir 2007, 23:12261-12268.
98. Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J 1869, 14:146-147.
99. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123:1991-2006.